|
A Phase II Study in Patients with Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma Clinical Trials Information presented on Clinical Trials Search isn't intended to be a substitute for proven healthcare advice, trips or treatment using a real physician. We are not docs. Always confer with your mD on A Phase II Study in Patients with Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. A Phase II Study in Patients with Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma Clinical research trials and A Phase II Study in Patients with Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectiveness of new drugs. The intention of the studies / projects is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector corporations to detect remedies for all forms of circumstances, like A Phase II Study in Patients with Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma. A Phase II Study in Patients with Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma Clinical Trials and other clinical trials allow for volunteers to undergo healthcare treatment options before they are available to the masses. Most times the participants receive treatment for free, and every now and again they are paid for their time. Occasionally there is a cost for a A Phase II Study in Patients with Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma clinical trial. Subjects typically recieve the finest healthcare available for their A Phase II Study in Patients with Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma condition. Hazards are a reality, nonetheless, and might include more or frequent mD trips, health risks (potentially life-endangering), and/or the treatment being ineffective. Trials are federally regulated with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Phase II Study in Patients with Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma  A Phase II Study in Patients with Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma
A Phase II Study in Patients with Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma
For Condition: Primary Peritoneal Carcinoma,Persistent or Recurrent Ovarian Cancer
Status: Not yet recruiting
Sponsor(s): Bristol-Myers Squibb , ImClone Systems
Synopsis: The purpose of this study is to determine the overall response rate, time to progression, and 1 yr survival with cetuximab in patients with ovarian or primary peritoneal carcinoma.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Female
Protocol Entry Criteria: Inclusion Criteria: - subjects must have recurrent or persistent epithelial ovarian or primary peritoneal carcinoma. Histologic confirmation of the original primary tumor is required. - EGFR expression must be positive as determined by an outside reference lab - Subjects must have had a treatment-free interval following platinum of <12 mos - All subjects must have measureable disease at baseline - Subjects must have at least one recurrent lesion to be used to assess response - Recovery from effect of recent surgery, radiotherapy or chemotherapy Exclusion Criteria: - Subjects with other invasive malignancies (including peritoneal mesotheliomas) - Subjects with unstable cardiac disease or MI within 6 mos - Subjects with Acute hepatitis - Subjects with active or uncontrolled infection - A history of prior cetuximab or other therapy which targets the EGFR pathway or prior history of prior chimerized or murine monoclonal antibody therapy
Total Enrollment: 50
Location and Contact Information:
Memorial Sloan-Kettering Cancer Center
New York City, New York, 10021
United States
Carol Aghajanian 212-639-2252
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111
United States
Russell Schilder 215-728-3545
M.D. Anderson Cancer Center
Houston, Texas, 77030
United States
David Gershenson 713-745-2565
Pacific Gynecology Specialists
Seattle, Washington, 09104
United States
Charles Drescher 206-215-3200
University of Alabama at Birmingham
Birmingham, Alabama, 35233
United States
Ronald Alvarez 205-975-6714
Additional Information:
Study ID Numbers: CA225-046;
Study Start Date:
Record last reviewed: November 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00082212
Other Primary Peritoneal Carcinoma Studies:
1. A Phase II Study in Patients with Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma
Related Studies:
Other Primary Peritoneal Carcinoma Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials
A Phase II Study in Patients with Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma
|
|
|
|
|
|
|
|
